公开(公告)号：US20210220404A1

公开(公告)日：2021-07-22

申请号：US17104983

申请日：2020-11-25

Applicant: Michael R. Greene ,  Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Attilio Bondanza ,  Jennifer Brogdon ,  Dexiu Bu ,  Serena De Vita ,  Glenn Dranoff ,  Boris Engels ,  Tony Fleming ,  Brian Walter Granda ,  Michael R. Greene ,  Carla Patricia Guimaraes ,  Anniesha Hack ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Olja Kodrasi ,  Joni Waiee Lam ,  Hyungwook Lim ,  Elizabeth Dorothy Pratico ,  Andrew Price ,  Akash Sohoni ,  Andrew Marc Stein ,  Louise Treanor ,  Chonghui Zhang ,  Xu Zhu

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

公开(公告)号：US20210002377A1

公开(公告)日：2021-01-07

申请号：US16884867

申请日：2020-05-27

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/24 ,  C12N5/0783

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

公开(公告)号：US20200339651A1

公开(公告)日：2020-10-29

申请号：US16708397

申请日：2019-12-09

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Gregory Beatty ,  David Jonathan Glass ,  Carl H. June ,  Joan Mannick ,  Michael C. Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu

IPC: C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K31/436 ,  A61K31/675 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.

公开(公告)号：US10662247B2

公开(公告)日：2020-05-26

申请号：US15517867

申请日：2015-10-08

Applicant: NOVARTIS AG

Inventor： Jennifer Brogdon ,  Daniela Cipolletta ,  Glenn Dranoff ,  Deborah A. Knee ,  Fei Wang

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06

Abstract: The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof.

公开(公告)号：US20190388471A1

公开(公告)日：2019-12-26

申请号：US16435257

申请日：2019-06-07

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Carl H. June ,  David L. Porter ,  Marcela Maus ,  Mariusz Wasik ,  Saar Gill ,  Joseph A. Fraietta ,  Marco Ruella ,  John Byrd ,  Jason Dubovsky ,  Amy Johnson ,  Natarajan Muthusamy ,  Saad Kenderian ,  Joan Mannick ,  David Jonathan Glass ,  Leon Murphy ,  Jennifer Brogdon ,  William Raj Sellers

IPC: A61K35/17 ,  A61K39/395 ,  A61K31/519 ,  A61K45/06 ,  C07K14/725 ,  A61K31/436 ,  A61K31/53 ,  C12N5/0783 ,  C07K16/28

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：US10287354B2

公开(公告)日：2019-05-14

申请号：US15105074

申请日：2014-12-19

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K31/436 ,  A61K35/17 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N9/90 ,  C07K14/74

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：US10221245B2

公开(公告)日：2019-03-05

申请号：US14214728

申请日：2014-03-15

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Carl H. June ,  Andreas Loew ,  Marcela Maus ,  John Scholler

IPC: C07K16/30 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.

公开(公告)号：US20190000944A1

公开(公告)日：2019-01-03

申请号：US16065387

申请日：2016-12-21

Applicant: Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe ,  Novartis AG ,  The Trustees of the University of Pennsylvania ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20180334490A1

公开(公告)日：2018-11-22

申请号：US15529246

申请日：2015-12-02

Applicant: Jennifer Brogdon ,  Gregory Beatty ,  David Glass ,  Carl H. June ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Gregory Beatty ,  David Glass ,  Carl H. June ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu

IPC: C07K14/725 ,  A61P35/00 ,  A61K35/17 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K38/17 ,  A61K39/395 ,  A61K31/675 ,  A61K31/436 ,  A61N5/10

CPC classification number: C07K14/7051 ,  A61K31/436 ,  A61K31/675 ,  A61K35/00 ,  A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5256 ,  A61K2039/545 ,  A61N5/10 ,  A61N2005/1098 ,  A61P35/00 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.

公开(公告)号：US20180312595A1

公开(公告)日：2018-11-01

申请号：US15726703

申请日：2017-10-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Saar Gill ,  David Jonathan Glass ,  Saad Kenderian ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  David L. Porter ,  Marco Ruella ,  Yongqiang Wang ,  Qilong Wu ,  Jiquan Zhang

IPC: C07K16/28 ,  A61K39/00 ,  C12N5/0783 ,  C07K16/24

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.